Navigation Links
Igenica Closes $33 Million in Series C Funding
Date:6/12/2012

BURLINGAME, Calif., June 12, 2012 /PRNewswire/ -- Igenica, Inc., a leading biopharmaceutical company focused on the discovery and development of first-in-class antibodies, today announced that it has raised $33 million in a Series C round of funding.  The financing round was led by new investor Third Rock Ventures, with participation from existing investors The Column Group, Orbimed Advisors and 5AM Ventures.  The closing of the Series C financing increases the total raised by the company to $55 million since the company began operations in January 2009.

Proceeds from the financing will be used to advance the company's monoclonal antibody pipeline toward clinical trials.  These funds will also be used to apply Igenica's unique discovery approach, consisting of the sTAg target discovery platform and the iTAb antibody discovery platform, toward the discovery of new monoclonal antibodies against a broad range of drug targets that have not been previously investigated for the treatment of cancer.

"We are pleased to have Third Rock Ventures, a premier life sciences venture capital firm, lead Igenica's Series C round," said David Goeddel, Ph.D., Executive Chairman of Igenica, Inc.  "Third Rock's investment highlights the broad potential of Igenica's antibody technology and provides strategic flexibility as we execute our operating and business plans.  Moreover, we are now advancing a product candidate toward the clinic that has the potential to improve treatment outcomes for cancer patients."

About Igenica, Inc.
Igenica, Inc. is a biopharmaceutical company pioneering breakthrough antibody-based cancer medicines. The company has integrated innovative technology platforms to address the major challenges to developing effective treatments for multiple oncology indications, with sTAg, a new approach to discovering and prioritizing novel tumor antigens, and iTAb, a functional in vivo antibody screening approach. Collectively, the two technology platforms drive Igenica's drug discovery efforts and promise to identify novel and more effective cancer therapeutics.

Igenica's Board of Directors includes David Goeddel, Ph.D., Managing Partner, The Column Group; John Diekman, Ph.D., Managing Partner, 5AM Ventures; Mark A. Goldsmith, M.D., Ph.D., Venture Partner, Third Rock Ventures; Carl Gordon, Ph.D., CFA, General Partner, Orbimed Advisors; Robert Schreiber, Ph.D., Alumni Endowed Professor of Pathology and Immunology, Professor of Molecular Microbiology and Tumor Immunology Program Leader for the Siteman Comprehensive Cancer Center at Washington University School of Medicine.

Contact:

John K. Celebi, MBA
Chief Business Officer
Igenica, Inc.
(650) 231-4320


'/>"/>
SOURCE Igenica, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. C8 MediSensors Closes $19 million Preferred Stock Financing
2. Boston Scientific Closes Cameron Health Acquisition
3. Stereotaxis Closes $18.5 Million Private Placement Financings
4. Independa Closes Convertible Note Funding at $2.35 Million
5. Novelos Therapeutics Prices $5.4 Million Public Offering
6. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
7. InnoPharma Inc. Raises $8 Million in Venture Debt
8. University of Michigans Wolverine Venture Fund Participates in $25 Million Series D Investment in Sonitus Medical
9. Software Pioneer Leaves $10 Million Bequest To Five Leading Non-profits In Health And Drug Policy Reform
10. AssureRx Health Raises $12.5 Million Series C Financing
11. AcelRx Pharmaceuticals Announces Pricing of a $10.0 Million PIPE Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 , , , WHEN: ... 2016 , , , , LOCATION: , , , Online, ... , , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global ... Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager ... pharmaceutical industry is witnessing an exceptional era. Several new demand spaces, ...
(Date:6/23/2016)... , June 23, 2016 Revolutionary ... Oticon , industry leaders in advanced audiology ... of Oticon Opn ™, the world,s first internet ... possibilities for IoT devices.      (Photo: ... introduces a number of ,world firsts,: , ...
(Date:6/23/2016)... Research and Markets has announced the addition ... States, China, Japan, Brazil, United Kingdom, Germany, France, Italy, ... Surgical Procedure Volumes: Global ... surgical procedure volume data in a geographic context. The ... of growth drivers and inhibitors, including world population growth, ...
Breaking Medicine Technology:
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
Breaking Medicine News(10 mins):